AbbVie’s tavapadon, an investigational oral once-daily dopamine D1/D5 partial agonist, is nearing a potential regulatory submission, bolstered by new post-hoc…
Read More
OZMOSI and Planview Forge Strategic Alliance to Revolutionize Pharmaceutical R&D Planning with AI-Powered Clinical Intelligence
OZMOSI and Planview have announced a significant partnership aimed at transforming how pharmaceutical organizations approach research and development (R&D) planning.…
Read More
AI Governance and Trust: The Bedrock for Scaling Innovation in Drug Development
The accelerating adoption of artificial intelligence (AI) within the pharmaceutical industry is not merely a technological advancement; it is a…
Read More
Enanta Pharmaceuticals Poised to Lead Emerging RSV Therapeutics Market as Zelicapavir Advances to Phase III
Enanta Pharmaceuticals is strategically positioned to capture a significant share of the largely undeveloped market for respiratory syncytial virus (RSV)…
Read More
AbbVie Invests $1.4 Billion in North Carolina for New Manufacturing Hub
AbbVie, a global biopharmaceutical leader, has announced a landmark $1.4 billion investment to establish its first manufacturing facility in North…
Read More
Sanofi Receives FDA Approval to Expand Tzield Use in Children as Young as One Year for Type 1 Diabetes Delay
Sanofi has secured a significant expansion of its U.S. Food and Drug Administration (FDA) approval for Tzield (teplizumab-mzwv), a groundbreaking…
Read More
Idvynso Secures FDA Approval, Charting a New Course in HIV Treatment While Biktarvy Maintains Market Dominance
MSD (Merck & Co) has achieved a significant milestone in the fight against Human Immunodeficiency Virus (HIV) with the U.S.…
Read More
The Evolving Landscape of Locally Advanced Head and Neck Squamous Cell Carcinoma Treatment Presents New Avenues for Innovation
The treatment paradigm for locally advanced head and neck squamous cell carcinoma (LA HNSCC) is undergoing a significant transformation, driven…
Read More
US Government Assumes Full Cost of Weight Loss Drugs for Medicare Beneficiaries Through Extended GLP-1 Bridge Program Amidst Insurer Hesitation
The Centers for Medicare & Medicaid Services (CMS) has announced a significant extension of its Medicare GLP-1 Bridge program, shifting…
Read More
Ray Therapeutics Secures $125 Million Series B Funding to Accelerate Vision Restoration Pipeline
Ray Therapeutics, a biopharmaceutical company at the forefront of developing novel gene therapies for vision restoration, has successfully closed a…
Read More
